David Hansen

David Hansen is President and CEO of MabVax Therapeutics Holdings, Inc. He is a senior corporate executive with diverse and in-depth experience in the biopharmaceutical business. Mr. Hansen has proven leadership abilities in creating, building, and directing small startup operations and key departments in both large and small biopharmaceutical companies. He has broad therapeutic area expertise, including oncology and immunology. He has had direct responsibility for corporate and commercial development functions, including in and out licensing, product acquisition, strategic planning and new product planning. Most recently, Mr. Hansen was Senior Vice President of Corporate Development at Avanir Pharmaceuticals, a company focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. Prior to that, he was a Founder, President and COO of Xenerex Biosciences, a monoclonal antibody company focusing on development of fully human antibody products.